Search

Your search keyword '"Julian, Thomas B"' showing total 148 results
Start Over Author "Julian, Thomas B" Search Limiters Academic (Peer-Reviewed) Journals
148 results on '"Julian, Thomas B"'

1. Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Author

Geyer, Jr., Charles E., Bandos, Hanna, Rastogi, Priya, Jacobs, Samuel A., Robidoux, André, Fehrenbacher, Louis, Ward, Patrick J., Polikoff, Jonathan, Brufsky, Adam M., Provencher, Louise, Paterson, Alexander H. G., Hamm, John T., Carolla, Robert L., Baez-Diaz, Luis, Julian, Thomas B., Swain, Sandra M., Mamounas, Eleftherios P., and Wolmark, Norman

Published
2022
Full Text
View/download PDF

5. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

Author

Mamounas, Eleftherios P., Tang, Gong, Paik, Soonmyung, Baehner, Frederick L., Liu, Qing, Jeong, Jong-Hyeon, Kim, S. Rim, Butler, Steven M., Jamshidian, Farid, Cherbavaz, Diana B., Sing, Amy P., Shak, Steven, Julian, Thomas B., Lembersky, Barry C., Lawrence Wickerham, D., Costantino, Joseph P., and Wolmark, Norman

Published
2018
Full Text
View/download PDF

6. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

Author

Ganz, Patricia A, Cecchini, Reena S, Julian, Thomas B, Margolese, Richard G, Costantino, Joseph P, Vallow, Laura A, Albain, Kathy S, Whitworth, Patrick W, Cianfrocca, Mary E, Brufsky, Adam M, Gross, Howard M, Soori, Gamini S, Hopkins, Judith O, Fehrenbacher, Louis, Sturtz, Keren, Wozniak, Timothy F, Seay, Thomas E, Mamounas, Eleftherios P, and Wolmark, Norman

Published
2016
Full Text
View/download PDF

7. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

Author

Margolese, Richard G, Cecchini, Reena S, Julian, Thomas B, Ganz, Patricia A, Costantino, Joseph P, Vallow, Laura A, Albain, Kathy S, Whitworth, Patrick W, Cianfrocca, Mary E, Brufsky, Adam M, Gross, Howard M, Soori, Gamini S, Hopkins, Judith O, Fehrenbacher, Louis, Sturtz, Keren, Wozniak, Timothy F, Seay, Thomas E, Mamounas, Eleftherios P, and Wolmark, Norman

Published
2016
Full Text
View/download PDF

15. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

Author

Siziopikou, Kalliopi P., Anderson, Stewart J., Cobleigh, Melody A., Julian, Thomas B., Arthur, Douglas W., Zheng, Ping, Mamounas, Eleftherios P., Pajon, Eduardo R., Behrens, Robert J., Eakle, Janice F., Leasure, Nick C., Atkins, James N., Polikoff, Jonathan A., Seay, Thomas E., McCaskill-Stevens, Worta J., Rabinovitch, Rachel, Costantino, Joseph P., and Wolmark, Norman

Published
2013
Full Text
View/download PDF

16. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

Author

Krag, David N, Anderson, Stewart J, Julian, Thomas B, Brown, Ann M, Harlow, Seth P, Costantino, Joseph P, Ashikaga, Takamaru, Weaver, Donald L, Mamounas, Eleftherios P, Jalovec, Lynne M, Frazier, Thomas G, Noyes, R Dirk, Robidoux, André, Scarth, Hugh MC, and Wolmark, Norman

Published
2010
Full Text
View/download PDF

22. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis: CAGS and ACS evidence based reviews in surgery. 40

Author

Latosinsky, Steve, Berrang, Tanya S., Cutter, C. Suzanne, George, Ralph, Olivotto, Ivo, Julian, Thomas B., Hayashi, Allen, Baliski, Christopher, Croshaw, Randall L., Erb, Kathleen M., and Chen, Jennifer

Subjects
Metastasis -- Care and treatment, Breast -- Surgery, Breast cancer -- Care and treatment, Evidence-based medicine -- Practice, Health, Health care industry
Abstract

The term 'evidence-based medicine' was first coined by Sackett and colleagues as 'the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual [...]

Published
2012
Full Text
View/download PDF

25. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

Author

Boughey, Judy C., Suman, Vera J., Mittendorf, Elizabeth A., Ahrendt, Gretchen M., Wilke, Lee G., Taback, Bret, Leitch, Marilyn A., Kuerer, Henry M., Bowling, Monet, Flippo-Morton, Teresa S., Byrd, David R., Ollila, David W., Julian, Thomas B., McLaughlin, Sarah A., McCall, Linda, Symmans, Fraser W., Le-Petross, Huong T., Haffty, Bruce G., Buchholz, Thomas A., Nelson, Heidi, and Hunt, Kelly K.

Published
2013
Full Text
View/download PDF

27. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer

Author

Lehman, Constance D., Gatsonis, Constantine, Kuhl, Christiane K., Hendrick, R. Edward, Pisano, Etta D., Hanna, Lucy, Peacock, Sue, Smazal, Stanley F., Maki, Daniel D., Julian, Thomas B., DePeri, Elizabeth R., Bluemke, David A., and Schnall, Mitchell D.

Subjects
Magnetic resonance imaging -- Usage, Magnetic resonance imaging -- Analysis, Breast cancer -- Diagnosis, Mammography -- Methods, Mammography -- Analysis
Abstract

A study seeks to determine whether magnetic resonance imaging (MRI) can improve on clinical breast examination and mammography in detecting contralateral breast cancer soon after the initial diagnosis of unilateral breast cancer. Results show that MRI can detect cancer in the contralateral breast that is missed by mammography and clinical examination at the time of the initial breast-cancer diagnosis.

Published
2007

29. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial

Author

Krag, David N, Anderson, Stewart J, Julian, Thomas B, Brown, Ann M, Harlow, Seth P, Ashikaga, Takamaru, Weaver, Donald L, Miller, Barbara J, Jalovec, Lynne M, Frazier, Thomas G, Noyes, R Dirk, Robidoux, André, Scarth, Hugh MC, Mammolito, Denise M, McCready, David R, Mamounas, Eleftherios P, Costantino, Joseph P, and Wolmark, Norman

Published
2007
Full Text
View/download PDF

42. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.

Author

Cobleigh, Melody A, Anderson, Stewart J, Siziopikou, Kalliopi P, Arthur, Douglas W, Rabinovitch, Rachel, Julian, Thomas B, Parda, David S, Seaward, Samantha A, Carter, Dennis L, Lyons, Janice A, Dillmon, Melissa S, Magrinat, Gustav C, Kavadi, Vivek S, Zibelli, Allison M, Tiriveedhi, Lavanya, Hill, Matthew L, Melnik, Marianne K, Beriwal, Sushil, Mamounas, Eleftherios P, and Wolmark, Norman

Published
2021
Full Text
View/download PDF

45. The ongoing evaluation and evolution of breast cancer surgical care.

Author

Ferstenberg, Marielle and Julian, Thomas B.

Subjects
*BREAST tumors, *CANCER chemotherapy, *ONCOLOGIC surgery, *CANCER invasiveness, *COMBINED modality therapy, *DIAGNOSTIC imaging, *NEEDLE biopsy, *TUMOR classification
Abstract

Surgery has always been the backbone of breast cancer management. Throughout the past century, there have been great advances in chemotherapy regimens, especially in the neo‐adjuvant setting. As a result of this progress, a patient's disease can be potentially down‐staged and thus surgical intervention can therefore be de‐escalated for the breast as well as the axilla. Current clinical trials are evaluating the role of imaging and core needle biopsy as predictive tools for the efficacy of neo‐adjuvant chemotherapy. Results from these trials may help to clarify how the intricate relationship among imaging, pathology, radiotherapy, and surgery will affect the future management of patients undergoing neo‐adjuvant chemotherapy for invasive breast cancer. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

47. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy.

Author

Armer, Jane M., Ballman, Karla V., McCall, Linda, Armer, Nathan C., Sun, Yuanlu, Udmuangpia, Tipparat, Hunt, Kelly K., Mittendorf, Elizabeth A., Byrd, David R., Julian, Thomas B., and Boughey, Judy C.

Subjects
LYMPHEDEMA, ARM measurement, BREAST cancer patients, SYMPTOMS, ADJUVANT treatment of cancer, AXILLARY lymph node dissection, CANCER chemotherapy
Abstract

Purpose: Lymphedema is a potential complication of breast cancer treatment. This longitudinal substudy aimed to prospectively assess arm measurements and symptoms following neoadjuvant chemotherapy and axillary dissection in the ACOSOG/Alliance Z1071 trial to characterize the optimal approach to define lymphedema.Methods: Z1071 enrolled patients with cT0-4, N1-2, M0 disease treated with neoadjuvant chemotherapy. All patients underwent axillary dissection. Bilateral limb volumes, circumferences, and related symptoms were assessed pre-surgery, 1-2 weeks post-surgery, and semiannually for 36 months. Lymphedema definitions included volume increase ≥ 10% or limb circumference increase ≥ 2 cm. Symptoms were assessed by the Lymphedema Breast Cancer Questionnaire.Results: In 488 evaluable patients, lymphedema incidence at 3 years by ≥ 10%-volume-increase was 60.3% (95% CI 55.0-66.2%) and by ≥ 2 cm-circumference increase was 75.4% (95% CI 70.8-80.2%). Symptoms of arm swelling and heaviness decreased from post-surgery for the first 18 months and then were relatively stable. The 3-year cumulative incidence of arm swelling and heaviness was 26.0% (95% CI 21.7-31.1%) and 30.9% (95% CI 26.3-36.3%), respectively. There was limited agreement between the two measurements (kappa 0.27) and between symptoms and measurements (kappa coefficients ranging from 0.05-0.09).Conclusions: Lymphedema incidence by limb volume and circumference gradually increased over 36 months post-surgery, whereas lymphedema symptoms were much lower. These findings underscore the importance of prospective surveillance and evaluation of both limb measurements and symptom assessment. Lymphedema incidence rates varied by definition. We recommend that ≥ 10% volume change criterion be used for lymphedema evaluation for referral for specialist care.Trial Registration: NCT00881361. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

48. Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.

Author

Jayasekera, Jinani, Li, Yisheng, Schechter, Clyde B, Jagsi, Reshma, Song, Juhee, White, Julia, Luta, George, Chapman, Judith-Anne W, Feuer, Eric J, Zellars, Richard C, Stout, Natasha, Julian, Thomas B, Whelan, Timothy, Huang, Xuelin, Hwang, E Shelley, Hopkins, Judith O, Sparano, Joseph A, Anderson, Stewart J, Fyles, Anthony W, and Gray, Robert

Subjects
CLINICAL trials, BREAST cancer treatment, RADIOTHERAPY, HORMONE therapy, EPIDERMAL growth factor receptors
Abstract

Background: We used two models to simulate a proposed noninferiority trial of radiotherapy (RT) omission in low-risk invasive breast cancer to illustrate how modeling could be used to predict the trial's outcomes, inform trial design, and contribute to practice debates.Methods: The proposed trial was a prospective randomized trial of no-RT vs RT in women age 40 to 74 years undergoing lumpectomy and endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, stage I breast cancer with an Oncotype DX score of 18 or lower. The primary endpoint was recurrence-free interval (RFI), including locoregional recurrence, distant recurrence, and breast cancer death. Noninferiority required the two-sided 90% confidence interval of the RFI hazard ratio (HR) for no-RT vs RT to be entirely below 1.7. Model inputs included published data. The trial was simulated 1000 times, and results were summarized as percent concluding noninferiority and mean (standard deviation) of hazard ratios for Model GE and Model M, respectively.Results: Noninferiority was demonstrated in 18.0% and 3.7% for the two models. The respective means (SD) of the RFI hazard ratios were 1.8 (0.7) and 2.4 (0.9); most were locoregional recurrences. The mean five-year RFI rates for no-RT vs RT (SD) were 92.7% (2.9%) vs 95.5% (2.2%) and 88.4% (2.0%) vs 94.5% (1.6%). Both models showed little or no difference in breast cancer-specific or overall survival. Alternative definitions of low risk based on combinations of age and grade produced similar results.Conclusions: The proposed trial was unlikely to show noninferiority of omitting radiotherapy even using alternative definitions of low-risk, as the endpoint included local recurrence. Future trials regarding radiotherapy should address absolute reduction in recurrence and impact of type of recurrence on the patient. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.

Author

Jayasekera, Jinani, Schechter, Clyde B, Sparano, Joseph A, Jagsi, Reshma, White, Julia, Chapman, Judith-Anne W, Whelan, Timothy, Anderson, Stewart J, Fyles, Anthony W, Sauerbrei, Willi, Zellars, Richard C, Li, Yisheng, Song, Juhee, Huang, Xuelin, Julian, Thomas B, Luta, George, Berry, Donald A, Feuer, Eric J, Mandelblatt, Jeanne, and Group, CISNET-BOLD Collaborative

Subjects
RADIOTHERAPY, BREAST cancer treatment, HORMONES, GENE expression, MEDICAL care
Abstract

Background: Radiotherapy after breast conservation has become the standard of care. Prior meta-analyses on effects of radiotherapy predated availability of gene expression profiling (GEP) to assess recurrence risk and/or did not include all relevant outcomes. This analysis used GEP information with pooled individual-level data to evaluate the impact of omitting radiotherapy on recurrence and mortality.Methods: We considered trials that evaluated or administered radiotherapy after lumpectomy in women with low-risk breast cancer. Women included had undergone lumpectomy and were treated with hormonal therapy for stage I, ER+ and/or PR+, HER2- breast cancer with Oncotype scores no greater than 18. Recurrence-free interval (RFI), type of RFI (locoregional or distant), and breast cancer-specific and overall survival were compared between no radiotherapy and radiotherapy using adjusted Cox models. All statistical tests were two-sided.Results: The final sample included 1778 women from seven trials. Omission of radiotherapy was associated with an overall adjusted hazard ratio of 2.59 (95% confidence interval [CI] = 1.38 to 4.89, P = .003) for RFI. There was a statistically significant increase in any first locoregional recurrence (P = .001), but not distant recurrence events (P = .90), or breast cancer-specific (P = .85) or overall survival (P = .61). Five-year RFI rate was high (93.5% for no radiotherapy vs 97.9% for radiotherapy; absolute reduction = 4.4%, 95% CI = 0.7% to 8.1%, P = .03). The effects of radiotherapy varied across subgroups, with lower RFI rates for those with Oncotype scores of less than 11 (vs 11-18), older (vs younger), and ER+/PR+ status (vs other).Conclusions: Omission of radiotherapy in hormone-sensitive patients with low recurrence risk may lead to a modest increase in locoregional recurrence event rates, but does not appear to increase the rate of distant recurrence or death. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results